PATENT CLAIM ANALYSIS

Application Number: 16322227
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-06
Patent Classification: ["544", "278000"]

Abstract:
An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.

Claim (Index 2):
The pharmaceutical composition according to  claim 1 ,\n wherein the pharmaceutically acceptable salt is 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid choline salt.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 99.0
- Lexical Diversity: 1.22667
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15942802', '15647911', '13577832', '16020436', '11715509']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7631031860618382
- 35 USC 102 Novelty (BERT): 0.4964874657487055
- Combined Prediction Score: 0.736441614030525
- Mean Citation Score: 183.093914
- Max Citation Score: 195.25916
- Similarity Product: 121.96051102163791

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test